Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

es' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether the results of the Phase IIb trial are predictive of results in subsequent trials of tezampanel, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's drug development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel will successfully treat migraine pain, that NGX267 will successfully treat the symptoms of cognitive impairment associated with schizophrenia, that NGX267 will successfully treat xerostomia or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel or NGX267. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31,2006 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is lik
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
(Date:10/19/2014)... The Latin American hardware encryption display market report ... analysis and forecast of revenue. This market was valued ... reach $2,366.8 million by 2018, at a CAGR of ... TOC of the Latin American hardware encryption market report ... It also provides a glimpse of the segmentation of ...
(Date:10/19/2014)... 19, 2014 The Asia-Pacific Bromine ... in Asia-Pacific with analysis and forecast of revenue. ... Pacific Bromine Market report, to get an idea ... a glimpse of the segmentation in the Asia-Pacific ... and figures. , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , ...
(Date:10/19/2014)... The report "Chocolate, Cocoa Beans, Lecithin, Sugar and Vanilla ... Forecast (2011 - 2016)," analyzes the chocolate market ... major market drivers, restraints, and opportunities for the chocolate ... global chocolate market is expected to grow from $83.2 ... estimated CAGR of 2.7% from 2011 to 2016. , ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... Human Genome Sciences, Inc. (Nasdaq: HGSI ... Annual JPMorgan Healthcare Conference will be webcast and may ... )A member of Human Genome Sciences, senior management ... Wednesday, January 14, 2009 at 7:30 am Pacific Time ...
... Human Bionics Inc., "Victhom" (TSX: VHB), today announced ... www.victhom.com . The Website features a new ... operating divisions; Neurobionix, which is developing an implantable ... is developing and manufacturing computerized prostheses for above-knee ...
... SANTA CLARA, Calif., Jan. 9 GlaxoSmithKline and XenoPort, ... Drug Application (NDA) to the U.S. Food and Drug ... enacarbil) Extended Release Tablets for the treatment ... FDA had requested that the data in a single ...
Cached Biology Technology:Victhom Announces Launch of Enhanced Company Website 2GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome 2GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome 3
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
(Date:10/15/2014)... , Oct. 15, 2014 Sandata ... for home and community-based care, today announced it ... implementing Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™) ... is a home health company founded in 1996 ... . The study details ...
(Date:10/15/2014)... bacterial pneumonia in female mice to an enzyme activated ... naturally more resistant to respiratory infections than males. Now, ... resistance to bacterial pneumonia in female mice is linked ... also show that this enzyme is ultimately activated by ... The team, lead by Professor Lester Kobzik at the ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... - Strategies for pursuing an HIV cure, the impact ... innovative models for HIV testing and care feature heavily ... cures" and the benefits of early antiretroviral therapeutic treatment ... 20I3 conference, the worlds leading open HIV scientific forum, ...
... down cell walls faster leading to less ... systems are brought together in an industrial setting, ... Energy Laboratory suggests. A paper on the ... Synergistic Mechanisms in Cellulose Deconstruction," appears in the ...
... sensor deployed by Woods Hole Oceanographic Institution (WHOI) in Gulf ... or harmful algal blooms (HABs) are monitored and managed in ... last month, and a second such system will be deployed ... to weekly real-time forecasts of New England red tide this ...
Cached Biology News:IAS 2013 conference program live online 2IAS 2013 conference program live online 3Combining strategies speeds the work of enzymes 2New robotic instruments to provide real-time data on Gulf of Maine red tide 2New robotic instruments to provide real-time data on Gulf of Maine red tide 3New robotic instruments to provide real-time data on Gulf of Maine red tide 4
... Performance The TSQ Quantum Ultra defines ... bioanalytical and environmental analysis. It features ... APCI probes, a titanium skimmer with superior ... and sensitivity. Its redesigned ion transfer ...
... Cellular uptake of long double stranded RNA ... interference in a diverse group of organisms ... RNA interference leads to the inhibition of ... of the target messenger RNA (mRNA). Attempts ...
... a tetramethylrhodamine-conjugated jetSI-ENDO (excitation at ... nm), the powerful siRNA transfection ... to determine the transfection efficiency ... and trafficking of siRNAs. More ...
... and Bruker BioSpins Metabolic Profiler is ... and analysis of complex mixtures. It ... optional Avance NMR spectrometer and integrated ... statistical analysis for applications like:,Assessment of ...
Biology Products: